Cheryl Vickroy, MBA

President & CEO

Image of Cheryl Vickroy, MBA

Cheryl Vickroy leads the development of strategy and acquisition of funding for AmebaGone.  Cheryl is an experienced entrepreneur and a recognized expert in technology commercialization. She founded and served as CEO of Staff Management Systems in 2007. Vickroy played key, early-stage roles at Cellular Dynamics and Stem Cell Products (merged 2008, IPO 2013) and Genetic Assemblies Inc. (acquired 2005). 

From 2010-2014 she served as Director of the Center for Technology Commercialization where she created and implemented programs for research-based small business and led efforts to acquire over $60M in federal SBIR/STTR funding for clients across WI.  She has personally assisted many dozens of firms to assess feasibiilty of their innovations, to acquire over $35M in federal and equity funding and to develop successful commercial strategies.

Cheryl served twice as a mentor in the National Science Foundation Innovation Corps (I-Corps), leading teams to rapidly and accurately assess the market risk of novel technologies. She teaches Technology Commercialization in the Master of Science in Biotechnology Program at the Univeristy of Wisconsin-Madison. Previously, she served in a leadership role for a nationwide association where she managed over $20M in assets and led a staff of 54. 

cvickroy@amebagone.com

Marcin Filutowicz, Ph.D.

Founder and Chief Scientific Officer

Image of Marcin Filutowicz, Ph.D.Dr. Marcin Filutowicz, founded AmebaGone, Inc. in 2010 to commercialize a novel technology based upon the unique potential of free-living professional phagocytes (Dictyostelids or Dicty), found in soil and many other environments worldwide, to combat disease-causing microbes in affecting plants, water quality and human health. 

Dr. Filutowicz and Katarzyna Borys from the Bacteriology Department of University of Wisconsin-Madison conceived the core technology. The inventors have assigned title for their work to AmebaGone and have executed a license to a collection of source material amassed by Dr. Kenneth Raper (also UW-Madison) with the Wisconsin Alumni Research Foundation (WARF).  Filutowicz has developed biocontrol countermeasures to reduce infections caused by antibiotic-resistant bacteria since 1999. Dr. Filutowicz is a serial innovator, having co-founded ConjuGon Inc. in 2001 after inventing its technology. ConjuGon (now Atterx Biotherapeutics) is developing therapeutics to treat human bacterial infections. ConjuGon raised over $18M to advance its technology and is currently in Phase III clinical trials.

Dr. Filutowicz is a Professor of Bacteriology at University of Wisconsin-Madison where he joined the faculty in 1987 and has since been continuously funded. He received his Ph.D from the Polish Academy of Sciences. 

msfiluto@amebagone.com

In alphabetical order: Chad Hall, Ph.D., MBA

Senior Scientist

Image of In alphabetical order:  Chad Hall, Ph.D., MBADr. Chad Hall, PhD, MBA completed a BS in Genetics at University of Wisconsin-Madison followed by graduate training in the Department of Human and Molecular Genetics at Baylor College of Medicine in Houston, TX where his thesis focused on the identification of novel tumor suppressor genes and oncogenes through genome-wide screening in Drosophila. He discovered the Hippo pathway effector, Yap, is a potent ovarian cancer oncogene in flies and humans. During his PhD training he earned an MBA with a focus on entrepreneurship from the Jones School of Business at Rice University. Chad completed postdoctoral training in Oncology in the laboratory of Dr. Jeremy Graff at Eli Lilly and Co.  His work focused on deepening understanding of the mechanism of action of targeted therapies to identify and preselect patients more likely to benefit from therapy.  There, he gained a broad understanding of the scientific and business aspects of drug development. He then joined Centrose as a Senior Scientist where he led efforts to determine mechanism of action, patient tailoring strategy and drug combination strategy of their extracellular drug conjugates (EDCs) to guide clinical development.

Amy Jancewicz, Ph.D.

Scientist

Image of Amy Jancewicz, Ph.D.

Dr. Amy Jancewicz, Ph.D., joined Amebagone to contribute understanding of plant growth behaviors and the molecular mechanisms that govern them.  Amy received her PhD in Cellular and Molecular Biology from the University of Wisconsin-Madison. As a 2007 graduate of the University of Connecticut-Storrs with a BS in Molecular and Cellular Biology and BA in Sociology, she has nearly a decade of experience studying plant growth behaviors and those molecular mechanisms that govern them.

Courtney Trinastic

Research Specialist

Image of Courtney Trinastic

Courtney Trinastic joined Amebagone in 2017.  She holds a B.S. in Microbiology from the University of Wisconsin-Madison.  While studying for her degree, she worked in Dr. Marcin Filutowicz’s lab in the Department of Bacteriology at UW-Madison where she led a project to revive a source collection of Dicty along with researching interactions between Dicty and various biofilms. She also mentored several undergraduate students. She previously worked in the Biosafety Department at UW-Madison approving grants and amendments to lab protocols.

Kristi Freibergs

Technician

Image of Kristi Freibergs

Kristi Freibergs joined Amebagone as a lab technician in 2017 to work on revitalizing a source collection of Dicty.  She currently attends the University of Wisconsin-Madison where she is working toward her B.S. in Microbiology. While working in Dr. Marcin Filutowicz’s lab at the Department of Bacteriology in UW-Madison, Kristi contributed to the revitalization of a second Dicty collection and mentored several undergraduate students. Additionally, she researched the development of Dicty during their predation of bacteria.